The $67.5M and $75M revenue requirements that were mentioned in the call and briefing were referencing to two separate OrbiMed items.
$67.5M: If revenue is below $67.5M for the 12-months to December 31, 2024, they have to start repaying the OrbiMed loan in equal quarterly installments equal to 5.00%of the outstanding principal amount together with a repayment premium and other fees.
$75M: If revenue is above $75M on or prior to December 31, 2024, they'd be eligible to borrow the first $25M tranche.
Interesting q2 presentation, page-15
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.94 |
Change
-0.090(2.97%) |
Mkt cap ! $207.0M | |||
| Open | High | Low | Value | Volume |
| $3.00 | $3.00 | $2.92 | $298.6K | 101.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3416 | $2.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.98 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| AVH (ASX) Chart |